EUVIMEDEUVIMED entdecken
CrossrefInfokarte

The Safety, Pharmacokinetics, and Antiviral Activity of ABI ‐4334, A Novel Next‐Generation Hepatitis B Capsid Assembly Modulator

Edward J. Gane, Christian Schwabe, Nelli Ghicavii, Cristina Ticot, Katie Zomorodi, Steven J. Knox, Kathryn M. Kitrinos, Ran Yan, Jieming Liu, Grace Wang, Anuj Gaggar, Alina Jucov

Journal of Viral Hepatitis · 2026-12 · 33 (12)

DOI: 10.1111/jvh.70258 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Novel, well‐tolerated, short‐term therapeutics for chronic hepatitis B virus infection (cHBV) are needed. ABI‐4334 is a next‐generation capsid assembly modulator that targets the HBV core protein. The safety, tolerability, and pharmacokinetics of ABI‐4334 in healthy volunteers and participants with cHBV and antiviral effects in participants with cHBV were examined in two Phase 1 studies. Study 101 was a placebo‐controlled study of healthy volunteers that included four single‐ascending dose cohorts and two once‐daily multiple‐ascending dose cohorts randomized 6:2 (ABI‐4334:placebo), and one crossover food‐effect cohort randomized 3:3 (fed:fasted). Study 102 was a randomized, blinded, placebo‐controlled study where participants with cHBV were randomized 8:2 (ABI‐4334 [2 dose cohorts]:placebo). Overall, 54 healthy volunteers and 20 participants with cHBV were included in Studies 101 and 102, respectively. Most participants (75%) in Study 102 were hepatitis B e antigen (HBeAg) negative and generally had lower baseline HBV DNA and pregenomic RNA (pgRNA) levels. ABI‐4334 was well tolerated, with no treatment‐emergent serious adverse events (AEs) or treatment‐emergent AEs leading to study discontinuation. The mean ABI‐4334 plasma half‐life ranges were comparable across doses in both studies. Following multiple‐dose administration in participants with cHBV, the steady‐state mean plasma half‐life ranged from 17.5 to 27.5 h. HBV DNA declines were observed in both HBeAg‐positive ( n = 3) and ‐negative ( n = 13) participants across doses. Reductions in pgRNA were observed in participants with detectable pgRNA at baseline. ABI‐4334 was well tolerated, with pharmacokinetics and antiviral results supporting the continued development of ABI‐4334 as a monotherapy or component of novel combination regimens for cHBV. Trial Registration: Study 101 (NCT05569941). Study 102 (NCT06384131)

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →